

OPEN ACCESS

EDITED AND REVIEWED BY
Gabriel Sandblom,
Karolinska Institutet (KI), Sweden

*CORRESPONDENCE
Markus M. Heiss
✉ heissm@kliniken-koeln.de

RECEIVED 15 May 2023
ACCEPTED 17 May 2023
PUBLISHED 13 June 2023

CITATION
Heiss MM, Schafmayer C and Gutschow CA
(2023) Editorial: Endoscopic vacuum therapy
(EVT) in the gastrointestinal tract—a paradigm
shift in the surgical treatment and prevention of
anastomotic insufficiencies and perforations.
Front. Surg. 10:1222993.
doi: 10.3389/fsurg.2023.1222993

COPYRIGHT
© 2023 Heiss, Schafmayer and Gutschow. This
is an open-access article distributed under the
terms of the [Creative Commons Attribution
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that the
original publication in this journal is cited, in
accordance with accepted academic practice.
No use, distribution or reproduction is
permitted which does not comply with these
terms.

Editorial: Endoscopic vacuum therapy (EVT) in the gastrointestinal tract—a paradigm shift in the surgical treatment and prevention of anastomotic insufficiencies and perforations

Markus M. Heiss^{1*}, Clemens Schafmayer² and
Christian A. Gutschow³

¹Department of Abdominal, Tumor, Transplant and Vascular Surgery, Cologne-Merheim Medical Center, Witten/Herdecke University, Cologne, Germany, ²General, Visceral, Thorax, Vascular and Transplantation Surgery, Rostock University Medical Center, Rostock, Germany, ³Department of Visceral and Transplant Surgery, University Hospital Zurich, Zurich, Switzerland

KEYWORDS

endoscopic vacuum therapy, EVT, gastrointestinal wall defect, anastomotic leakage, VACStent, preemptive therapy of anastomotic suture line

Editorial on the Research Topic

[Endoscopic vacuum therapy \(EVT\) in the gastrointestinal tract—a paradigm shift in the surgical treatment and prevention of anastomotic insufficiencies and perforations](#)

Endoluminal vacuum therapy (EVT) has proven to be a very effective and safe method of treating perforations and suture leaks in both the upper and lower gastrointestinal tract and has gained wide clinical acceptance in recent years (1).

In dehiscences with larger extraluminal wound cavities, intracavitary sponge placement has been recommended to achieve optimal debridement of the contaminated area. However, mediastinal vascular erosion with subsequent hemorrhage or airway fistulas remain a major concern, especially when high negative pressure is used. Therefore, luminal sponge placement, or even conversion to other modalities such as stent or VACStent placement is recommended once the extraluminal cavity is contained and granulated.

However, EVT with luminal sponge placement raises the issue of obstruction, which can be overcome, albeit with difficulty, by placing a feeding tube. The VACStent offers an alternative way to ensure safe closure of the intestinal wall defect while preserving intestinal passage and allowing early enteral nutrition (Schäfer et al. “Don’t be afraid of black holes: Vacuum sponge and vacuum stent treatment of leaks in the upper GI tract—a case series and mini-review”). In addition, experience to date shows that the VACStent is easy and safe to use, thus combining EVT with the advantages of covered stenting (Lange et al. “Clinical implantation of 92 VACStents in the upper gastrointestinal tract of 50 patients—applicability and safety analysis of an innovative endoscopic concept”). The sponge cylinder around the stent fixes the device to the intestinal wall like a suction cup and seals it against the intestinal lumen together with the somewhat protruding stent

ends. In the lower GI tract, the VACStent allows effective EVT while maintaining stool passage and avoiding a stoma.

Recent clinical results show that EVT is indeed able to deliver on this promise and avert the potentially catastrophic consequences of esophageal perforation or anastomotic leakage with success rates of 80-100% (Pattynama et al. "Vacuum-stent: A combination of endoscopic vacuum therapy and an intraluminal stent for treatment of esophageal transmural defects"). This is also true for duodenal lesions if the defect is technically and endoscopically accessible (Wichmann et al. "Endoscopic negative pressure therapy for duodenal leaks").

The treatment of gastrointestinal leaks with EVT has reduced both morbidity and mortality, leading to a real paradigm shift. The traditional principle of aggressive surgical therapy plus drainage can now very often be replaced by an endoscopic approach, avoiding extensive, complicated revision surgery with often serious consequences for the patient. EVT is therefore one of the most important innovations in surgery in recent decades.

Nevertheless, the development of EVT is only at its beginning. There is growing evidence that early prophylactic use of EVT can prevent anastomotic leakage or their sequelae in both the upper and lower GI tracts (Schiffmann et al. "SEVTAR—A multicenter randomized controlled trial to investigate the impact of prophylactic endoluminal placed vacuum sponge for prevention of anastomotic leakage after low rectal resections"), which can be explained by improved wound healing due to the mechanisms of EVT, especially enhanced microperfusion (2). Even if suture leakage occurs under preemptive EVT, the suction drainage of the sponge or sponge cylinder effectively prevents the formation of a larger wound cavity and the development of sepsis. Anastomotic leakage thus loses its clinical horror and can heal without consequences (Lange et al. "Preemptive endoluminal vacuum therapy with the VACStent—A pilot study to reduce anastomotic leakage after Ivor Lewis hybrid

esophagectomy"). If this is confirmed in the ongoing and planned studies, EVT would become an integral part of any major surgery which includes anastomosis in endoscopically accessible regions. This would have a significant positive impact on the clinical outcome and the financial burden of surgical complication treatment.

Author contributions

All authors contributed in preparation of the editorial and approved the submitted version. All authors contributed to the article and approved the submitted version.

Conflict of interest

The authors declare a potential conflict of interest and state it below. MH holds a patent (suction stent for sealing a leakage, international publication number: WO 2015/086037 A1) and is a senior consultant for Moeller Medical GmbH, Fulda, Germany.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Richter F, Hendricks A, Schniewind B, Hampe J, Heits N, von Schönfels W, et al. Eso-Sponge® for anastomotic leakage after oesophageal resection or perforation: outcomes from a national, prospective multicentre registry. *BJS Open*. (2022) 6(2): zrac030. doi: 10.1093/bjsopen/zrac030
2. Müller PC, Morell B, Vetter D, Raptis DA, Kapp JR, Gubler C, et al. Preemptive endoluminal vacuum therapy to reduce morbidity after minimally invasive ivor lewis esophagectomy: including a novel grading system for postoperative endoscopic assessment of GI-anastomoses. *Ann Surg*. (2021) 274(5):751–7. doi: 10.1097/SLA.0000000000005125

VAC Stent GmbH
Wasserkuppenstraße 29-31
36043 Fulda, Germany
dschlecht@moeller-medical.com

MÖLLER Medical GmbH
Wasserkuppenstrasse 29-31
36043 Fulda, Germany
info@moeller-medical.com

